EA200700380A1 - CONJUGATES OF GLYCEROLICOLORBED POLYETHYLENE GLYCOL - HUMAN GROWTH HORMONE, METHOD OF THEIR PRODUCTION AND METHODS OF THEIR APPLICATION - Google Patents

CONJUGATES OF GLYCEROLICOLORBED POLYETHYLENE GLYCOL - HUMAN GROWTH HORMONE, METHOD OF THEIR PRODUCTION AND METHODS OF THEIR APPLICATION

Info

Publication number
EA200700380A1
EA200700380A1 EA200700380A EA200700380A EA200700380A1 EA 200700380 A1 EA200700380 A1 EA 200700380A1 EA 200700380 A EA200700380 A EA 200700380A EA 200700380 A EA200700380 A EA 200700380A EA 200700380 A1 EA200700380 A1 EA 200700380A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
growth hormone
human growth
glycerolicolorbed
conjugates
Prior art date
Application number
EA200700380A
Other languages
Russian (ru)
Inventor
Рори Ф. Финн
Нед Р. Сиджел
Original Assignee
Фармация Энд Апджон Компани Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200700380(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фармация Энд Апджон Компани Ллс filed Critical Фармация Энд Апджон Компани Ллс
Publication of EA200700380A1 publication Critical patent/EA200700380A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Настоящее изобретение относится к ПЭГилированию гормона роста человека (hGH) с использованием глицеринразветвленного ПЭГ. Настоящее изобретение также относится к способам ПЭГилирования hGH. Кроме того, настоящее изобретение относится к фармацевтическим композициям, включающим ПЭГилированный hGH. Еще один вариант осуществления включает использование ПЭГилированного hGH для лечения нарушений роста и развития.The present invention relates to the PEGylation of human growth hormone (hGH) using glycerol branched PEG. The present invention also relates to methods for PEGylation of hGH. In addition, the present invention relates to pharmaceutical compositions comprising PEGylated hGH. Another embodiment includes the use of PEGylated hGH for the treatment of growth and development disorders.

EA200700380A 2004-08-31 2005-08-25 CONJUGATES OF GLYCEROLICOLORBED POLYETHYLENE GLYCOL - HUMAN GROWTH HORMONE, METHOD OF THEIR PRODUCTION AND METHODS OF THEIR APPLICATION EA200700380A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60594504P 2004-08-31 2004-08-31
PCT/IB2005/002939 WO2006024953A2 (en) 2004-08-31 2005-08-25 Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof

Publications (1)

Publication Number Publication Date
EA200700380A1 true EA200700380A1 (en) 2007-10-26

Family

ID=35708806

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700380A EA200700380A1 (en) 2004-08-31 2005-08-25 CONJUGATES OF GLYCEROLICOLORBED POLYETHYLENE GLYCOL - HUMAN GROWTH HORMONE, METHOD OF THEIR PRODUCTION AND METHODS OF THEIR APPLICATION

Country Status (24)

Country Link
EP (1) EP1789092A2 (en)
JP (1) JP2008511610A (en)
KR (1) KR20070042567A (en)
CN (1) CN101010105A (en)
AP (1) AP2007003919A0 (en)
AR (1) AR050851A1 (en)
AU (1) AU2005278903A1 (en)
BR (1) BRPI0515118A (en)
CA (1) CA2577999A1 (en)
CR (1) CR8942A (en)
EA (1) EA200700380A1 (en)
EC (1) ECSP077281A (en)
GT (1) GT200500235A (en)
IL (1) IL181085A0 (en)
MA (1) MA28908B1 (en)
MX (1) MX2007002441A (en)
NL (1) NL1029828C2 (en)
NO (1) NO20071322L (en)
PE (1) PE20060654A1 (en)
TN (1) TNSN07078A1 (en)
TW (1) TW200621291A (en)
UY (1) UY29088A1 (en)
WO (1) WO2006024953A2 (en)
ZA (1) ZA200701802B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
AU751898B2 (en) 1997-07-14 2002-08-29 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
ES2373093T3 (en) 1999-01-14 2012-01-31 Bolder Biotechnology, Inc. METHODS TO PREPARE PROTEINS CONTAINING FREE CYSTEINE REMAINS.
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
EP2023959A4 (en) * 2006-05-12 2011-06-08 Dong A Pharm Co Ltd Polyethylene glycol-interferon alpha conjugate
JP2008069073A (en) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd Lactoferrin conjugate and its manufacturing method
KR101079993B1 (en) 2006-11-17 2011-11-04 동아제약주식회사 Polyethylene glycol-G-CSF conjugate
CL2008002399A1 (en) 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
UA101670C2 (en) * 2008-07-23 2013-04-25 Ханми Сайенс Ко., Лтд. Polypeptide complex comprising non-peptidyl polymer having three functional ends
EA020347B1 (en) 2008-07-31 2014-10-30 Фармаиссэншиа Корп. Peptide-polymer conjugates
NZ603964A (en) * 2008-10-10 2014-12-24 Polyactiva Pty Ltd Biodegradable polymer - bioactive moiety conjugates
US8535655B2 (en) 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
EP2340271B1 (en) * 2008-10-10 2018-12-05 PolyActiva Pty Ltd. Polymer-bioactive agent conjugates
MX2011008094A (en) 2009-02-03 2012-02-13 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same.
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CN102612376A (en) 2009-08-06 2012-07-25 诺沃-诺迪斯克保健股份有限公司 Growth hormones with prolonged in-vivo efficacy
CN101831067A (en) * 2010-05-31 2010-09-15 王二新 Polyethylene glycol ester conjugate and application thereof in medicine preparation
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
CN102367290B (en) * 2011-04-26 2013-05-08 厦门赛诺邦格生物科技有限公司 Chain-functionalized multi-level branched polyethylene glycol and synthesis method thereof
EP2947111B1 (en) * 2013-01-17 2018-03-07 Xiamen Sinopeg Biotech Co., Ltd. Monofunctional branched polyethyleneglycol and bio-related substance modified by same
CN104877127B (en) 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 A kind of eight arms polyethyleneglycol derivative, preparation method and its bio-related substance of modification
EP3215193B1 (en) 2014-11-06 2023-10-04 PharmaEssentia Corporation Dosage regimen for pegylated interferon
KR102523239B1 (en) * 2017-12-29 2023-04-18 에프. 호프만-라 로슈 아게 Methods for Providing Pegylated Protein Compositions
ES2905105T3 (en) 2017-12-29 2022-04-07 Hoffmann La Roche Procedure for Providing a PEGylated Protein Composition
EP3731873B1 (en) * 2017-12-29 2022-01-26 F. Hoffmann-La Roche AG Process for providing pegylated protein composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
JP3092531B2 (en) * 1996-11-05 2000-09-25 日本油脂株式会社 Method for producing imidyl succinate-substituted polyoxyalkylene derivative
AU751898B2 (en) * 1997-07-14 2002-08-29 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
JP3921781B2 (en) * 1998-02-12 2007-05-30 日本油脂株式会社 Carboxyl group-containing polyoxyalkylene compound
ES2373093T3 (en) * 1999-01-14 2012-01-31 Bolder Biotechnology, Inc. METHODS TO PREPARE PROTEINS CONTAINING FREE CYSTEINE REMAINS.
BR0214451A (en) * 2001-11-20 2006-05-30 Pharmacia Corp chemically modified human growth hormone conjugates
ES2897470T3 (en) * 2002-09-09 2022-03-01 Nektar Therapeutics Water soluble polymeric alkanals
JP4412461B2 (en) * 2002-11-20 2010-02-10 日油株式会社 Modified bio-related substance, production method thereof and intermediate
AU2003303519C1 (en) * 2002-12-31 2010-08-12 Nektar Therapeutics Polymeric reagents comprising a ketone or a related functional group
PT2644206T (en) * 2003-05-23 2019-07-10 Nektar Therapeutics Peg derivatives containing two peg chains

Also Published As

Publication number Publication date
TW200621291A (en) 2006-07-01
AR050851A1 (en) 2006-11-29
JP2008511610A (en) 2008-04-17
CR8942A (en) 2007-08-16
ECSP077281A (en) 2007-03-29
MX2007002441A (en) 2007-05-04
NL1029828A1 (en) 2006-03-01
CN101010105A (en) 2007-08-01
KR20070042567A (en) 2007-04-23
WO2006024953A3 (en) 2007-01-18
NL1029828C2 (en) 2006-10-20
PE20060654A1 (en) 2006-08-12
AU2005278903A1 (en) 2006-03-09
BRPI0515118A (en) 2008-07-01
IL181085A0 (en) 2007-07-04
TNSN07078A1 (en) 2008-06-02
CA2577999A1 (en) 2006-03-09
AP2007003919A0 (en) 2007-02-28
WO2006024953A2 (en) 2006-03-09
ZA200701802B (en) 2008-08-27
GT200500235A (en) 2006-03-21
EP1789092A2 (en) 2007-05-30
NO20071322L (en) 2007-05-29
MA28908B1 (en) 2007-10-01
UY29088A1 (en) 2006-03-31

Similar Documents

Publication Publication Date Title
EA200700380A1 (en) CONJUGATES OF GLYCEROLICOLORBED POLYETHYLENE GLYCOL - HUMAN GROWTH HORMONE, METHOD OF THEIR PRODUCTION AND METHODS OF THEIR APPLICATION
BRPI0418745A (en) cell line antibody, pharmaceutical composition, and method of treating cancer in a patient
EA200601776A1 (en) METADONIC COMPOSITIONS OF LOCAL ACTION AND METHODS OF THEIR APPLICATION
ATE531382T1 (en) TREATMENT METHODS OF INFLAMMATORY DISEASES WITH ACTIVE INGREDIENTS SPECIFICALLY BINDING TO HUMAN ANGIOPOIETIN-2
BRPI0317376B8 (en) antibody-il2 fusion protein designated as hu14.18-il2, uses thereof, vector and pharmaceutical composition
BRPI0406605B8 (en) protein conjugate, method for its preparation and pharmaceutical composition to enhance the duration and in vivo stability of a physiologically active polypeptide
BRPI0618488A2 (en) Hepatocyte Growth Factor Intron Fusion Proteins
BRPI0813699A2 (en) GLP-1-FC FUSION PROTEIN FORMULATIONS
DK1180121T3 (en) Long-acting insulinotropic peptides
ATE374043T1 (en) STABILIZED COMPOSITIONS CONTAINING A THERAPEUTIC ACTIVE SUBSTANCE; CITRIC ACID OR A CONJUGATE BASE AND CHLORINE DIOXIDE
EA200700175A1 (en) COMPOSITIONS AND METHODS OF TREATING INFLAMMATORY DISEASES
DE60223254D1 (en) DELAYED FORCULATING FORMULATIONS OF OXYMORPHONE
DK1715887T3 (en) N-terminal Monopegylated Human Growth Hormone Conjugates, Methods for their Preparation and Use
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
MX2009006893A (en) Pharmaceutical compositions and method for treating inflammation in cattle and other animals.
EA201001569A1 (en) Incapsulation of biologically active agents
DK2229440T3 (en) RECOMBINANT ELASTASE PROTEINS AND PROCEDURES FOR PRODUCING AND USING THEREOF
EA200501821A1 (en) PHARMACEUTICAL COMBINATION, CONTAINING MODAFINIL AND OTHER DRUG PREPARATION
EA200701072A1 (en) PREPARATIONS FOR BENZHOIAZOLE AND THEIR USE
WO2007134118A3 (en) Protein based composition and methods of using same
EA200601392A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF LIPODYSTROPHY
DK1596879T3 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
DK1537132T3 (en) Salt of Mortin-6-Glucuronide
EA200600314A1 (en) USE OF SOLUBLE CD164 IN INFLAMMATORY AND / OR AUTOMAINED DISORDERS
DOP2005000172A (en) CONJUGATES OF HUMAN GROWTH HORMONES AND POLYETHYLENGLYCOL RAMIFIED WITH GLICEROL, PROCESS FOR PREPARATION AND METHOD OF USE OF THE SAME